Zealand Logo (1).png
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
December 10, 2024 09:00 ET | Zealand Pharma
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the...
zealand_logo_RGB_01.png
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
June 20, 2024 11:37 ET | Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
zealand_logo_RGB_01.png
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
May 31, 2024 10:03 ET | Zealand Pharma
Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency ...
zealand_logo_RGB_01.png
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
May 23, 2024 14:45 ET | Zealand Pharma
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
zealand_logo_RGB_01.png
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
January 08, 2024 15:45 ET | Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...
zealand_logo_RGB_01.png
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
January 02, 2024 02:00 ET | Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
zealand_logo_RGB_01.png
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
December 04, 2023 02:30 ET | Zealand Pharma
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and...
zealand_logo_RGB_01.png
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
November 30, 2023 02:00 ET | Zealand Pharma
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no....
zealand_logo_RGB_01.png
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
November 09, 2023 01:00 ET | Zealand Pharma
Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for...
zealand_logo_RGB_01.png
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
November 07, 2023 04:00 ET | Zealand Pharma
Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...